S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
Log in
OTCMKTS:GNMSF

Genmab A/S News Headlines

$456.83
+18.41 (+4.20 %)
(As of 01/15/2021 08:27 PM ET)
Add
Compare
Today's Range
$430.08
Now: $456.83
$456.83
50-Day Range
$375.01
MA: $398.24
$438.42
52-Week Range
$159.45
Now: $456.83
$456.83
Volume200 shs
Average Volume1,410 shs
Market Capitalization$28.18 billion
P/E Ratio6.49
Dividend YieldN/A
Beta0.83

Headlines

Genmab A/S (OTCMKTS GNMSF) News Headlines Today

Source:
SourceHeadline
Genmab A/S (OTCMKTS:GNMSF) Reaches New 52-Week High at $438.50Genmab A/S (OTCMKTS:GNMSF) Reaches New 52-Week High at $438.50
americanbankingnews.com - January 14 at 7:20 PM
Genmab A/S (OTCMKTS:GNMSF) Short Interest Up 97.4% in DecemberGenmab A/S (OTCMKTS:GNMSF) Short Interest Up 97.4% in December
americanbankingnews.com - January 14 at 6:08 AM
Genmab Achieves USD 40 Million Milestone in Collaboration with AbbVieGenmab Achieves USD 40 Million Milestone in Collaboration with AbbVie
finance.yahoo.com - January 13 at 9:46 AM
Genmab A/S (OTCMKTS:GNMSF) Share Price Crosses Above Fifty Day Moving Average of $394.24Genmab A/S (OTCMKTS:GNMSF) Share Price Crosses Above Fifty Day Moving Average of $394.24
americanbankingnews.com - January 13 at 4:56 AM
Genmab to Present at the 39th Annual J.P. Morgan Healthcare ConferenceGenmab to Present at the 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 6 at 12:19 PM
Genmab A/S (OTCMKTS:GNMSF) Hits New 12-Month High at $430.18Genmab A/S (OTCMKTS:GNMSF) Hits New 12-Month High at $430.18
americanbankingnews.com - January 5 at 6:42 PM
Genmab (GMAB) Begins Phase III Study on Cervical Cancer DrugGenmab (GMAB) Begins Phase III Study on Cervical Cancer Drug
finance.yahoo.com - January 5 at 4:10 PM
Genmab A/S (OTCMKTS:GNMSF) Reaches New 52-Week High at $410.41Genmab A/S (OTCMKTS:GNMSF) Reaches New 52-Week High at $410.41
americanbankingnews.com - December 30 at 6:38 PM
AbbVie (ABBV) Outperforms Industry Year to Date: Heres WhyAbbVie (ABBV) Outperforms Industry Year to Date: Here's Why
finance.yahoo.com - December 28 at 1:42 PM
Genmab A/S (OTCMKTS:GNMSF) Stock Crosses Above Fifty Day Moving Average of $380.11Genmab A/S (OTCMKTS:GNMSF) Stock Crosses Above Fifty Day Moving Average of $380.11
americanbankingnews.com - December 25 at 4:22 AM
Stocks Showing Improved Relative Strength: Revance TherapeuticsStocks Showing Improved Relative Strength: Revance Therapeutics
finance.yahoo.com - December 23 at 2:21 PM
Sarepta Therapeutics Sees Relative Strength Rating Improve To 74Sarepta Therapeutics Sees Relative Strength Rating Improve To 74
finance.yahoo.com - December 9 at 3:15 PM
Sarepta Therapeutics Earns Relative Strength Rating UpgradeSarepta Therapeutics Earns Relative Strength Rating Upgrade
finance.yahoo.com - December 7 at 3:47 PM
Genmab Announces that Janssen has Submitted a Biologics License Application to U.S. FDA for Amivantamab in Non-small Cell Lung CancerGenmab Announces that Janssen has Submitted a Biologics License Application to U.S. FDA for Amivantamab in Non-small Cell Lung Cancer
finance.yahoo.com - December 3 at 4:14 PM
Genmab Announces Enapotamab Vedotin UpdateGenmab Announces Enapotamab Vedotin Update
finance.yahoo.com - November 24 at 11:23 AM
Genmab to Present at Jefferies Virtual London Healthcare ConferenceGenmab to Present at Jefferies Virtual London Healthcare Conference
finance.yahoo.com - November 10 at 9:10 AM
Genmab A/S (GMAB) Q3 2020 Earnings Call TranscriptGenmab A/S (GMAB) Q3 2020 Earnings Call Transcript
fool.com - November 5 at 4:37 AM
Genmab Announces IFM, HOVON and Janssen Achieve Positive Topline Results in Second Part of Phase 3 CASSIOPEIA Study of Daratumumab in Multiple Myeloma at Pre-planned Interim AnalysisGenmab Announces IFM, HOVON and Janssen Achieve Positive Topline Results in Second Part of Phase 3 CASSIOPEIA Study of Daratumumab in Multiple Myeloma at Pre-planned Interim Analysis
finance.yahoo.com - October 21 at 6:10 PM
Genmab and Seattle Genetics Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020Genmab and Seattle Genetics Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020
finance.yahoo.com - September 21 at 1:27 PM
Genmab Announces that Janssen has Submitted a Supplemental Biologics License Application to U.S. FDA for use of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) in Patients with Light-chain (AL) AmyloidosisGenmab Announces that Janssen has Submitted a Supplemental Biologics License Application to U.S. FDA for use of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) in Patients with Light-chain (AL) Amyloidosis
finance.yahoo.com - September 10 at 8:34 AM
Genmab to Present at Morgan Stanley 18th Annual Global Healthcare ConferenceGenmab to Present at Morgan Stanley 18th Annual Global Healthcare Conference
finance.yahoo.com - September 9 at 1:01 PM
Genmab Announces Late-Breaking Oral Presentation of Phase 2 innovaTV 204 Study at the ESMO Virtual Congress 2020Genmab Announces Late-Breaking Oral Presentation of Phase 2 innovaTV 204 Study at the ESMO Virtual Congress 2020
finance.yahoo.com - August 26 at 6:39 PM
Kura Oncology Clears Key Benchmark, Hitting 90-Plus RS RatingKura Oncology Clears Key Benchmark, Hitting 90-Plus RS Rating
finance.yahoo.com - August 26 at 1:39 PM
Genmab Announces Plan to Transition Arzerra® (ofatumumab) to an Oncology Access Program for Chronic Lymphocytic Leukemia Patients in the U.S.Genmab Announces Plan to Transition Arzerra® (ofatumumab) to an Oncology Access Program for Chronic Lymphocytic Leukemia Patients in the U.S.
finance.yahoo.com - August 20 at 5:50 PM
Genmab Announces Janssen Granted U.S. FDA Approval for DARZALEX® (daratumumab) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple MyelomaGenmab Announces Janssen Granted U.S. FDA Approval for DARZALEX® (daratumumab) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
finance.yahoo.com - August 20 at 5:50 PM
Genmab A/S (GMAB) Q2 2020 Earnings Call TranscriptGenmab A/S (GMAB) Q2 2020 Earnings Call Transcript
finance.yahoo.com - August 12 at 10:50 PM
Genmab Announces Financial Results for the First Half of 2020Genmab Announces Financial Results for the First Half of 2020
finance.yahoo.com - August 12 at 12:50 PM
Genmab (GMAB) to Report Q2 Earnings: What's in the Cards?Genmab (GMAB) to Report Q2 Earnings: What's in the Cards?
finance.yahoo.com - August 3 at 12:00 PM
AbbVie Shares Climb After Adjusted Profit Beats Analyst ViewsAbbVie Shares Climb After Adjusted Profit Beats Analyst Views
finance.yahoo.com - July 31 at 10:07 AM
Genmab Announces Net Sales of DARZALEX® for the Second Quarter of 2020Genmab Announces Net Sales of DARZALEX® for the Second Quarter of 2020
finance.yahoo.com - July 16 at 7:52 AM
Can Genmab AS Sponsored ADR (GMAB) Run Higher on Rising Earnings Estimates?Can Genmab AS Sponsored ADR (GMAB) Run Higher on Rising Earnings Estimates?
finance.yahoo.com - June 16 at 1:14 PM
How Does Genmab's (CPH:GMAB) P/E Compare To Its Industry, After Its Big Share Price Gain?How Does Genmab's (CPH:GMAB) P/E Compare To Its Industry, After Its Big Share Price Gain?
finance.yahoo.com - May 13 at 3:00 AM
Genmab A/S 2020 Q1 - Results - Earnings Call PresentationGenmab A/S 2020 Q1 - Results - Earnings Call Presentation
seekingalpha.com - May 6 at 4:09 PM
Should We Worry About Genmab A/S's (CPH:GMAB) P/E Ratio?Should We Worry About Genmab A/S's (CPH:GMAB) P/E Ratio?
finance.yahoo.com - April 15 at 7:51 AM
Is Now The Time To Put Genmab (CPH:GMAB) On Your Watchlist?Is Now The Time To Put Genmab (CPH:GMAB) On Your Watchlist?
finance.yahoo.com - February 26 at 6:20 AM
Genmab A/S (GMAB) Q4 2019 Earnings Call TranscriptGenmab A/S (GMAB) Q4 2019 Earnings Call Transcript
www.fool.com - February 19 at 11:07 PM
Genmab A/S 2019 Q4 - Results - Earnings Call PresentationGenmab A/S 2019 Q4 - Results - Earnings Call Presentation
seekingalpha.com - February 19 at 2:51 PM
European advisory group backs expanded label for J&Js DarzalexEuropean advisory group backs expanded label for J&J's Darzalex
seekingalpha.com - October 18 at 11:09 AM
What Should Investors Know About The Future Of Genmab A/S's (CPH:GMAB)?What Should Investors Know About The Future Of Genmab A/S's (CPH:GMAB)?
finance.yahoo.com - August 14 at 5:19 PM
Genmab up 2% in Europe on Q2 Darzalex salesGenmab up 2% in Europe on Q2 Darzalex sales
seekingalpha.com - July 16 at 10:28 AM
Janssen files U.S. application for subcutaneous DarzalexJanssen files U.S. application for subcutaneous Darzalex
seekingalpha.com - July 12 at 4:51 PM
Genmab teams up with BliNK Biomedical to develop bispecific antibodiesGenmab teams up with BliNK Biomedical to develop bispecific antibodies
seekingalpha.com - July 12 at 10:20 AM
J&Js Darzalex shows treatment effect in mid-stage study in certain MM patientsJ&J's Darzalex shows treatment effect in mid-stage study in certain MM patients
seekingalpha.com - July 8 at 4:56 PM
BlackRock cuts stake in GenmabBlackRock cuts stake in Genmab
seekingalpha.com - June 25 at 5:16 PM
Genmab A/S 2019 Q1 - Results - Earnings Call SlidesGenmab A/S 2019 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 13 at 5:38 PM
Why Earnings Season Could Be Great for Genmab (GNMSF)Why Earnings Season Could Be Great for Genmab (GNMSF)
finance.yahoo.com - May 13 at 5:38 PM
Global Blood (GBT) Reports Narrower-Than-Expected Loss in Q1Global Blood (GBT) Reports Narrower-Than-Expected Loss in Q1
www.msn.com - May 10 at 5:18 PM
Amicus' (FOLD) Earnings & Revenues Miss Estimates in Q1Amicus' (FOLD) Earnings & Revenues Miss Estimates in Q1
finance.yahoo.com - May 9 at 5:24 PM
What's in the Cards for AcelRx (ACRX) This Earnings Season?What's in the Cards for AcelRx (ACRX) This Earnings Season?
finance.yahoo.com - May 7 at 5:28 PM
Seattle Genetics Adcetris Progresses Well Amid CompetitionSeattle Genetics' Adcetris Progresses Well Amid Competition
finance.yahoo.com - April 11 at 11:49 AM
This page was last updated on 1/18/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.